Why SpaceX Investors Must Watch Blue Origin

The article argues SpaceX’s $1.75T valuation (~100x trailing revenue) assumes limited competitive pressure, but it flags Blue Origin as a credible emerging rival backed by a sharp federal-contract acceleration (+177% vs the prior rate under Trump) and new approvals for up to $2.4B in Space Force launch work. It cites the federal funding gap since 2008—about $24.9B for SpaceX vs ~$2.6B for Blue Origin—while emphasizing operational disparities (SpaceX launches every 2–3 days and has 8,000+ Starlink satellites vs New Glenn’s early-stage landings). For SpaceX investors, the key risk is potential deliberate allocation of government funds to sustain a second supplier, which could cap SpaceX’s pricing power and contract share despite superior execution.

Analysis

This is less a near-term launch-demand story than a multiple story: the market has been paying SPCX as if the dominance were durable enough to justify monopoly-like economics, and that premium is now at risk of being diluted by policy-driven second sourcing. The key second-order effect is not that Blue Origin must match SpaceX operationally; it only needs to be credible enough to win a mandated slice of government work, which is enough to cap pricing power and reduce the implied terminal margin assumption.

For public comps like RKLB and RDW, the read-through is mixed. They can benefit from a broader procurement pool and a larger addressable market if agencies intentionally diversify suppliers, but they are still too far behind in cadence and scale to capture meaningful displacement share quickly. In other words, this is more likely to support backlog visibility and sentiment than to translate into immediate multiple expansion unless contract conversion and launch frequency accelerate materially.

Catalyst-wise, the next 1-3 months matter most around award cadence, budget language, and whether the Pentagon/NASA continue formalizing second-provider capacity. The thesis weakens if SpaceX keeps winning the lion’s share of major programs and Starship milestones continue to widen the cost gap; over 6-18 months, a true reusability breakthrough would reassert the moat. The contrarian point: the market may be underpricing how quickly procurement policy can erode an economic moat even when the technical moat remains intact.

Key Decisions for Investors

• Reduce/hedge SPCX exposure on rallies if liquid access exists; this is a 6-12 month multiple-compression trade, not an immediate earnings short. Falsifier: sustained acceleration in major federal award share for SpaceX or clear Starship commercialization progress.
• Maintain only a small tactical long in RKLB on pullbacks as a diversification optionality trade tied to government second-sourcing; size modest because contract intent does not yet equal margin conversion.
• Do not chase RDW here; treat it as a sentiment beneficiary at best, but not a clean fundamental winner unless backlog and gross margin inflect over the next 2-3 quarters.
• Set a watch item on the next NASA/Space Force award cycle: if Blue Origin wins another material block, that is the signal to add to SPCX downside hedges; if not, fade the scare and assume the monopoly premium was only partially dented.